UBS Group AG - TSCAN THERAPEUTICS INC ownership

TSCAN THERAPEUTICS INC's ticker is and the CUSIP is 89854M101. A total of 33 filers reported holding TSCAN THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 1.3%.

Quarter-by-quarter ownership
UBS Group AG ownership history of TSCAN THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,854
+3.8%
1,115
+1.4%
0.00%
Q2 2023$2,750
-59.6%
1,100
-66.0%
0.00%
Q1 2023$6,804
+339.0%
3,240
+224.0%
0.00%
Q4 2022$1,550
-85.9%
1,000
-70.9%
0.00%
Q3 2022$11,000
+175.0%
3,441
+199.7%
0.00%
Q2 2022$4,0000.0%1,148
+41.6%
0.00%
Q4 2021$4,000
-50.0%
811
-14.3%
0.00%
Q3 2021$8,0009460.00%
Other shareholders
TSCAN THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
DC Funds, LP 630,000$1,323,00030.82%
Deer Management Co. LLC 1,245,505$2,615,5610.24%
Simplify Asset Management Inc. 546,916$1,148,5240.16%
Alphabet Inc. 1,077,080$2,261,8680.12%
Newtyn Management, LLC 236,800$497,2800.10%
DC Investments Management, LLC 35,563$74,6820.09%
Privium Fund Management (UK) Ltd 15,825$40,9870.03%
Baker Brothers Advisors 2,784,792$5,848,0630.03%
Tekla Capital Management LLC 200,000$420,0000.02%
NewEdge Wealth, LLC 91,463$192,0720.01%
View complete list of TSCAN THERAPEUTICS INC shareholders